Market Newsdesk

August 4, 2026 9:44 pm

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion

Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion

Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent Acquisitions

FOSTER CITY, Calif.–(BUSINESS WIRE)–
Please replace the release with the following corrected version due to a change in the “PRODUCT SALES SUMMARY” table, where the Odefsey sales in Europe have been updated to $58 million for the three months ended June 30, 2026 (instead of $28 million).

The updated release reads:

GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion

Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion

Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent Acquisitions

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026.

“Gilead delivered a very strong second quarter, with 10% year-over-year revenue growth in our base business driven by our HIV portfolio, Trodelvy and Livdelzi. HIV sales grew 12%, reflecting continued strength in treatment and the rapid expansion of our PrEP business, supporting an increase in our base business revenue expectations for 2026,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “We also made significant clinical progress with three FDA approvals and three positive Phase 3 updates. We look forward to delivering on our many opportunities in the second half of the year including another two potential launches in oncology and HIV.”

Second Quarter 2026 Financial Results

Total second quarter 2026 revenues increased 10% to $7.8 billion compared to the same period in 2025, primarily driven by:
- Higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy) and Livdelzi® (seladelpar), partially offset by lower sales of Veklury® (remdesivir) as well as Cell Therapy and chronic hepatitis C virus (“HCV”) products; and
- Higher royalty, contract and other revenues related to a previous sale of intellectual property.
Diluted (loss) earnings per share (“EPS”) was $(8.45) in the second quarter 2026 compared to $1.56 in the same period in 2025. The decrease was primarily driven by the $(9.08) per share impact of acquired in-process research and development (“IPR&D”) expenses associated with our acquisitions of Arcellx, Inc. (“Arcellx”), Tubulis GmbH (“Tubulis”) and Ouro Medicines, LLC (“Ouro Medicines”), net of the impact of our collaboration with Lakefront Biotherapeutics NV (“Lakefront”) and the related taxes, as well as an IPR&D impairment related to assets previously acquired from Immunomedics, Inc. (“Immunomedics”) and higher operating expenses. The decrease was partially offset by higher revenues, lower income tax expense, and higher net gains from equity securities.
Non-GAAP diluted (loss) EPS was $(6.75) in the second quarter 2026 compared to $2.01 in the same period in 2025. The decrease was primarily driven by the $(9.08) per share impact of acquired IPR&D and tax expenses discussed above, as well as higher non-GAAP selling, general and administrative (“SG&A”) expenses and non-GAAP income tax expense, partially offset by higher revenues.
As of June 30, 2026, Gilead had $3.2 billion of cash, cash equivalents and marketable debt securities compared to $10.6 billion as of December 31, 2025. The decrease was primarily driven by year-to-date cash outflows of $11.3 billion related to acquisitions, $2.8 billion of debt repayments, $2.1 billion of dividend payments and $774 million of common stock repurchases, partially offset by $4.1 billion of net proceeds from debt financing and $6.1 billion of operating cash flow.
During the second quarter 2026, Gilead generated $3.6 billion in operating cash flow.
During the second quarter 2026, Gilead paid dividends of $1.0 billion and repurchased $355 million of common stock.

Second Quarter 2026 Product Sales

Total second quarter 2026 product sales increased 8% to $7.6 billion compared to the same period in 2025. Total second quarter 2026 product sales excluding Veklury increased 10% to $7.6 billion compared to the same period in 2025, primarily due to higher sales of HIV products, Trodelvy and Livdelzi, partially offset by lower sales of Cell Therapy and HCV products.

HIV product sales increased 12% to $5.7 billion in the second quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price and demand.

Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.8 billion in the second quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price, favorable inventory dynamics and higher demand.
Descovy® (FTC 200mg/TAF 25mg) sales increased 48% to $967 million in the second quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price and demand.

The Liver Disease portfolio sales increased 10% to $877 million in the second quarter 2026 compared to the same period in 2025, primarily reflecting higher demand for Livdelzi, as well as chronic hepatitis B virus (“HBV”) products and Hepcludex® (bulevirtide-gmod), partially offset by lower sales for HCV products.

Veklury sales decreased 81% to $23 million in the second quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.

Cell Therapy product sales decreased 14% to $417 million in the second quarter 2026 compared to the same period in 2025, reflecting ongoing competitive headwinds.

Yescarta® (axicabtagene ciloleucel) sales decreased 12% to $346 million in the second quarter 2026 compared to the same period in 2025, primarily driven by in- and out-of-class competition.
Tecartus® (brexucabtagene autoleucel) sales decreased 24% to $70 million in the second quarter 2026 compared to the same period in 2025, primarily driven by in-class competition.

Trodelvy® (sacituzumab govitecan-hziy) sales increased 26% to $457 million in the second quarter 2026 compared to the same period in 2025, primarily driven by higher demand.

Second Quarter 2026 Product Gross Margin, Operating Expenses and Effective Tax Rate

Product gross margin remained relatively flat at 79.3% in the second quarter 2026 compared to 78.7% in the same period in 2025. Non-GAAP product gross margin also remained flat at 86.9% in the second quarter 2026 compared to the same period in 2025.
Research and development (“R&D”) expenses were $1.8 billion in the second quarter 2026 compared to $1.5 billion in the same period in 2025, primarily due to integration costs and other acquisition-related expenses, partially offset by lower oncology clinical study activity. Non-GAAP R&D expenses were $1.4 billion in the second quarter 2026 compared to $1.5 billion in the same period in 2025, primarily driven by lower oncology clinical study activity.
Acquired IPR&D expenses were $11.2 billion in the second quarter 2026, primarily related to $7.0 billion for the Arcellx acquisition, $3.1 billion for the Tubulis acquisition and $1.0 billion for the Ouro Medicines acquisition, net of the impact of the Lakefront collaboration.
SG&A expenses were $1.9 billion in the second quarter 2026 compared to $1.4 billion in the same period in 2025, primarily driven by integration costs related to the acquisitions and higher HIV promotional activities. Non-GAAP SG&A expenses were $1.5 billion in the second quarter 2026 compared to $1.4 billion in the same period in 2025, primarily due to higher HIV promotional activities.
The effective tax rate (“ETR”) was (2.4)% in the second quarter 2026 compared to 19.3% in the same period in 2025. The non-GAAP ETR was (11.4)% in the second quarter 2026 compared to 18.8% in the same period in 2025. These changes primarily reflect the non-deductible acquired IPR&D expenses related to our acquisitions of Arcellx, Tubulis, and Ouro Medicines.

Guidance and Outlook

For the full year 2026, Gilead now expects:

(in millions, except per share amounts)	August 4, 2026 Guidance		Comparison to May 7, 2026 Guidance
(in millions, except per share amounts)	Low End	High End	Comparison to May 7, 2026 Guidance
Product sales	$ 30,100	$ 30,400	Previously $30,000 to $30,400
Product sales excluding Veklury	$ 29,800	$ 30,100	Previously $29,400 to $29,800
Veklury	~ $300		Previously ~ $600
Diluted loss per share	$ (3.75)	$ (3.40)	Previously $(3.25) to $(2.85)
Non-GAAP diluted loss per share	$ (0.65)	$ (0.30)	Previously $(1.05) to $(0.65)

Our full year 2026 GAAP and non-GAAP diluted loss per share guidance includes the impact of approximately $9.08 due to acquired IPR&D charges of $11.1 billion related to the Arcellx, Tubulis and Ouro Medicines transactions, net of the impact of the Lakefront collaboration and related taxes.

Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2026 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below.

Key Updates Since Our Last Quarterly Release

Virology

Announced U.S. Food and Drug Administration (“FDA”) accepted a supplemental New Drug Application submission for Yeztugo® (lenacapavir) 300-mg tablets as a potential once-weekly oral formulation for HIV pre-exposure prophylaxis (“PrEP”), with a Prescription Drug User Fee Act target action date of February 2, 2027.
Announced positive Phase 3 results from the ISLEND-1 and ISLEND-2 trials, in partnership with Merck, evaluating an investigational long-acting oral treatment regimen of islatravir 2 mg and lenacapavir 300 mg in adults with HIV who are virologically suppressed and switched from Biktarvy (ISLEND-1) or standard of care antiretroviral regimens (ISLEND-2) to the once-weekly combination.
Received FDA accelerated approval for Hepcludex for the treatment of chronic hepatitis delta virus (“HDV”) infection in adults without cirrhosis or with compensated cirrhosis, which is now the first and only FDA-approved treatment for HDV in the U.S.
Announced a donation of 2,000 vials of remdesivir to the Republic of Uganda to support response efforts to the current outbreak of Ebola Bundibugyo virus disease (“BVD”). Remdesivir is not approved for the treatment of Ebola virus disease, including BVD, anywhere globally, and the safety and efficacy of this use is not known.

Oncology

Received FDA approval of Trodelvy for the first-line (“1L”) treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (“mTNBC”) as either a single agent for patients who are not candidates for PD-1/PD-L1 inhibitor-based therapy or in combination with Keytruda® (pembrolizumab) or Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph) for patients whose tumors express PD-L1 (CPS ≥10).
Announced European Commission marketing authorization for Trodelvy as a monotherapy for the treatment of adult patients with unresectable locally advanced or mTNBC who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1/PD-L1 inhibitor therapy.
Received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Trodelvy in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable locally advanced or mTNBC who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 (CPS≥10).
Announced the discontinuation of the Phase 3 EVOKE-03 study, in partnership with Merck, evaluating Trodelvy in combination with Keytruda® for the investigational treatment of 1L metastatic non-small cell lung cancer with high PD-L1 expression (TPS ≥50%). The decision was based on the recommendation of the external Data Monitoring Committee, following review of data from a pre-specified final analysis of progression-free survival and interim analysis of overall survival.
Presented new analyses at the 2026 American Society of Clinical Oncology meeting from the Phase 3 ASCENT-03 and ASCENT-04 studies evaluating Trodelvy with or without Keytruda® in 1L mTNBC, as well as new data on investigational anitocabtagene-autoleucel (“anito-cel”) clinical trial manufacturing experience in patients with newly diagnosed or relapsed/refractory multiple myeloma.
Presented updated Phase 1 results for KITE-753, an investigational bicistronic autologous CD19/CD20 CAR T-cell therapy for relapsed or refractory B-cell lymphoma at the 2026 European Hematology Association meeting.
Completed the acquisition of Tubulis for $3.15 billion in upfront consideration. This acquisition brings Gilead next-generation antibody-drug conjugate (“ADC”) assets, including GS-8824, a NaPi2b-directed topoisomerase-I inhibitor ADC, and a platform to develop novel ADCs.

Inflammation

Completed the acquisition of Ouro Medicines for $1.675 billion in upfront consideration, which brings Gilead gamgertamig, an investigational clinical stage BCMAxCD3 T cell engager for autoimmune diseases. The acquisition was completed in collaboration with Lakefront, which equally shared the upfront payment and will equally share contingent milestone payments, subject to customary adjustments.
Announced positive results from the Phase 3 IDEAL study, supporting the potential of Livdelzi to help people living with primary biliary cholangitis (“PBC”) with elevated alkaline phosphatase (“ALP”) levels (between 1.0 and 1.67xULN) whose disease remains inadequately controlled despite treatment with ursodeoxycholic acid (“UDCA”), or who are intolerant to UDCA.
Presented data from the open-label Phase 3 ASSURE study at the 2026 European Association for the Study of the Liver Congress evaluating the long-term safety and tolerability profile of Livdelzi in people living with PBC with elevated ALP levels (between 1.0 and 1.67xULN) whose disease remains inadequately controlled despite treatment with UDCA, or who are intolerant to UDCA.

Corporate

Issued $3.0 billion aggregate principal amount of senior unsecured notes and borrowed $1.1 billion aggregate principal amount under a one-year term loan facility.
Announced a renewed 5-year collaboration with the World Health Organization to commit funding, strategic support and AmBisome donations toward eliminating visceral leishmaniasis.
The Board declared a quarterly dividend of $0.82 per share of common stock for the third quarter of 2026. The dividend is payable on September 29, 2026, to stockholders of record at the close of business on September 15, 2026. Future dividends will be subject to Board approval.

Certain amounts and percentages in this press release may not sum or recalculate due to rounding.

Conference Call

At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.

Non-GAAP Financial Information

The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets, restructuring charges and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities, the related tax charges or benefits associated with such exclusions and other discrete tax charges or benefits not representative of underlying trends such as changes in tax laws, transfers of intangible assets between certain legal entities, and effects of legal entity restructurings. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its full year 2026 financial guidance, including as a result of the uncertainty of the amount and timing of Veklury revenues, the impact from Medicare Part D pricing reform in the Inflation Reduction Act, the expiration of subsidies related to the Affordable Care Act, our most-favored-nation pricing agreement with the U.S. government, changes in U.S. regulatory or legislative policies, and changes in U.S. trade policies, including tariffs; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology, inflammation and other programs; Gilead’s ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the arrangements with Arcellx, Immunomedics, Lakefront, Merck, Ouro Medicines, The World Health Organization and Tubulis; the risk that Gilead’s U.S. manufacturing and R&D investment may not achieve their intended benefits; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving Livdelzi, Trodelvy, anito-cel, KITE-753 and lenacapavir (such as ASCENT-03, ASCENT-04, ASSURE, IDEAL, ISLEND-1 and ISLEND-2), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at all; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority, including those involving Hepcludex, Trodelvy and once-weekly oral Yeztugo; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies, including Hepcludex and Trodelvy; Gilead’s ability to effectively manage the access strategy relating to lenacapavir for HIV PrEP, subject to necessary regulatory approvals; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended June 30, 2026 are not necessarily indicative of operating results for any future periods.

Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Additional information is available on our Investor Relations website, https://investors.gilead.com. Among other things, an estimate of Acquired IPR&D expenses is expected to be made available on the Quarterly Results page within the first ten (10) days after the end of each quarter.

Gilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®, AMBISOME®, ATRIPLA®, BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, JYSELECA®, LIVDELZI®/LYVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and ZYDELIG®. Other trademarks and trade names are the property of their respective owners.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).


GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions, except per share amounts)		2026			2025			2026			2025
Revenues:
Product sales	$	7,627		$	7,054		$	14,574		$	13,668
Royalty, contract and other revenues		176			27			189			81
Total revenues		7,803			7,082			14,763			13,749
Costs and expenses:
Cost of goods sold		1,579			1,501			3,023			3,041
Research and development expenses		1,764			1,491			3,136			2,870
Acquired in-process research and development expenses		11,183			61			11,290			315
In-process research and development impairments		1,750			190			1,750			190
Selling, general and administrative expenses		1,921			1,365			3,372			2,623
Total costs and expenses		18,197			4,608			22,571			9,038
Operating (loss) income		(10,394	)		2,474			(7,808	)		4,711
Interest expense		247			254			487			513
Other (income) expense, net		(387	)		(208	)		(621	)		120
(Loss) income before income taxes		(10,254	)		2,429			(7,674	)		4,077
Income tax expense		242			468			801			802
Net (loss) income	$	(10,496	)	$	1,960		$	(8,475	)	$	3,275

Basic (loss) earnings per share	$	(8.45	)	$	1.57		$	(6.82	)	$	2.63
Diluted (loss) earnings per share	$	(8.45	)	$	1.56		$	(6.82	)	$	2.61

Shares used in basic (loss) earnings per share calculation		1,243			1,245			1,243			1,246
Shares used in diluted (loss) earnings per share calculation		1,243			1,255			1,243			1,257

Supplemental Information:
Cash dividends declared per share	$	0.82		$	0.79		$	1.64		$	1.58
Product gross margin		79.3	%		78.7	%		79.3	%		77.7	%
Research and development expenses as a % of revenues		22.6	%		21.1	%		21.2	%		20.9	%
Selling, general and administrative expenses as a % of revenues		24.6	%		19.3	%		22.8	%		19.1	%
Operating margin		(133.2	)%		34.9	%		(52.9	)%		34.3	%
Effective tax rate		(2.4	)%		19.3	%		(10.4	)%		19.7	%

GILEAD SCIENCES, INC. TOTAL REVENUE SUMMARY (unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions, except percentages)		2026		2025	Change			2026		2025	Change
Product sales:
HIV	$	5,693	$	5,088	12	%	$	10,723	$	9,675	11	%
Liver Disease		877		795	10	%		1,644		1,553	6	%
Oncology		873		849	3	%		1,683		1,606	5	%
Other		161		202	(20	)%		357		410	(13	)%
Total product sales excluding Veklury		7,604		6,934	10	%		14,406		13,245	9	%
Veklury		23		121	(81	)%		167		423	(60	)%
Total product sales		7,627		7,054	8	%		14,574		13,668	7	%
Royalty, contract and other revenues		176		27	NM			189		81	NM
Total revenues	$	7,803	$	7,082	10	%	$	14,763	$	13,749	7	%

____________________

NM – Not Meaningful

GILEAD SCIENCES, INC. NON-GAAP FINANCIAL INFORMATION⁽¹⁾ (unaudited)

	Three Months Ended								Six Months Ended
	June 30,								June 30,
(in millions, except percentages)		2026			2025		Change			2026			2025		Change
Non-GAAP:
Cost of goods sold	$	999		$	922		8	%	$	1,868		$	1,883		(1	)%
Research and development expenses	$	1,429		$	1,450		(1	)%	$	2,783		$	2,789		—	%
Acquired IPR&D expenses	$	11,183		$	61		NM		$	11,290		$	315		NM
Selling, general and administrative expenses	$	1,521		$	1,358		12	%	$	2,884		$	2,580		12	%
Other (income) expense, net	$	(44	)	$	(66	)	(33	)%	$	(137	)	$	(164	)	(17	)%
Diluted (loss) earnings per share	$	(6.75	)	$	2.01		NM		$	(4.70	)	$	3.82		NM
Shares used in non-GAAP diluted (loss) earnings per share calculation		1,243			1,255		(1	)%		1,243			1,257		(1	)%
Product gross margin		86.9	%		86.9	%	-3 bps			87.2	%		86.2	%	96 bps
Research and development expenses as a % of revenues		18.3	%		20.5	%	-217 bps			18.9	%		20.3	%	-143 bps
Selling, general and administrative expenses as a % of revenues		19.5	%		19.2	%	32 bps			19.5	%		18.8	%	77 bps
Operating margin		(93.9	)%		46.5	%	NM			(27.5	)%		45.0	%	NM
Effective tax rate		(11.4	)%		18.8	%	NM			(32.4	)%		17.6	%	NM

NM – Not Meaningful
⁽¹⁾	Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below.

GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION (unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions, except percentages and per share amounts)		2026			2025			2026			2025
Cost of goods sold reconciliation:
GAAP cost of goods sold	$	1,579		$	1,501		$	3,023		$	3,041
Acquisition-related – amortization⁽¹⁾		(579	)		(579	)		(1,155	)		(1,158	)
Restructuring		—			—			(1	)		—
Non-GAAP cost of goods sold	$	999		$	922		$	1,868		$	1,883

Product gross margin reconciliation:
GAAP product gross margin		79.3	%		78.7	%		79.3	%		77.7	%
Acquisition-related – amortization⁽¹⁾		7.6	%		8.2	%		7.9	%		8.5	%
Restructuring		—	%		—	%		—	%		—	%
Non-GAAP product gross margin		86.9	%		86.9	%		87.2	%		86.2	%

Research and development expenses reconciliation:
GAAP research and development expenses	$	1,764		$	1,491		$	3,136		$	2,870
Acquisition-related – other costs⁽²⁾		(333	)		(35	)		(336	)		(37	)
Restructuring		(2	)		(6	)		(17	)		(44	)
Non-GAAP research and development expenses	$	1,429		$	1,450		$	2,783		$	2,789

IPR&D impairment reconciliation:
GAAP IPR&D impairment	$	1,750		$	190		$	1,750		$	190
IPR&D impairment		(1,750	)		(190	)		(1,750	)		(190	)
Non-GAAP IPR&D impairment	$	—		$	—		$	—		$	—

Selling, general and administrative expenses reconciliation:
GAAP selling, general and administrative expenses	$	1,921		$	1,365		$	3,372		$	2,623
Acquisition-related – other costs⁽²⁾		(385	)		—			(385	)		—
Restructuring		(15	)		(7	)		(40	)		(43	)
Other⁽³⁾		—			—			(63	)		—
Non-GAAP selling, general and administrative expenses	$	1,521		$	1,358		$	2,884		$	2,580

Operating (loss) income reconciliation:
GAAP operating (loss) income	$	(10,394	)	$	2,474		$	(7,808	)	$	4,711
Acquisition-related – amortization⁽¹⁾		579			579			1,155			1,158
Acquisition-related – other costs⁽²⁾		718			35			721			37
Restructuring		17			13			57			88
IPR&D impairment		1,750			190			1,750			190
Other⁽³⁾		—			—			63			—
Non-GAAP operating (loss) income	$	(7,329	)	$	3,290		$	(4,062	)	$	6,183

Operating margin reconciliation:
GAAP operating margin		(133.2	)%		34.9	%		(52.9	)%		34.3	%
Acquisition-related – amortization⁽¹⁾		7.4	%		8.2	%		7.8	%		8.4	%
Acquisition-related – other costs⁽²⁾		9.2	%		0.5	%		4.9	%		0.3	%
Restructuring		0.2	%		0.2	%		0.4	%		0.6	%
IPR&D impairment		22.4	%		2.7	%		11.9	%		1.4	%
Other⁽³⁾		—	%		—	%		0.4	%		—	%
Non-GAAP operating margin		(93.9	)%		46.5	%		(27.5	)%		45.0	%

Other (income) expense, net reconciliation:
GAAP other (income) expense, net	$	(387	)	$	(208	)	$	(621	)	$	120
Gain (loss) from equity securities, net		343			142			485			(284	)
Non-GAAP other (income) expense, net	$	(44	)	$	(66	)	$	(137	)	$	(164	)

GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION – (Continued) (unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions, except percentages and per share amounts)		2026			2025			2026			2025
(Loss) income before income taxes reconciliation:
GAAP (loss) income before income taxes	$	(10,254	)	$	2,429		$	(7,674	)	$	4,077
Acquisition-related – amortization⁽¹⁾		579			579			1,155			1,158
Acquisition-related – other costs⁽²⁾		718			35			721			37
Restructuring		17			13			57			88
IPR&D impairment		1,750			190			1,750			190
(Gain) loss from equity securities, net		(343	)		(142	)		(485	)		284
Other⁽³⁾		—			—			63			—
Non-GAAP (loss) income before income taxes	$	(7,531	)	$	3,103		$	(4,412	)	$	5,834

Income tax expense reconciliation:
GAAP income tax expense	$	242		$	468		$	801		$	802
Income tax effect of non-GAAP adjustments:
Acquisition-related – amortization⁽¹⁾		119			120			236			241
Acquisition-related – other costs⁽²⁾		79			—			79			—
Restructuring		3			2			9			15
IPR&D impairment		415			51			415			51
(Gain) loss from equity securities, net		(42	)		(11	)		(108	)		10
Discrete and related tax charges⁽⁴⁾		44			(48	)		(2	)		(90	)
Non-GAAP income tax expense	$	860		$	583		$	1,430		$	1,029

Effective tax rate reconciliation:
GAAP effective tax rate		(2.4	)%		19.3	%		(10.4	)%		19.7	%
Income tax effect of above non-GAAP adjustments and discrete and related tax adjustments⁽⁴⁾		(9.1	)%		(0.5	)%		(22.0	)%		(2.0	)%
Non-GAAP effective tax rate		(11.4	)%		18.8	%		(32.4	)%		17.6	%

Net (loss) income reconciliation:
GAAP net (loss) income	$	(10,496	)	$	1,960		$	(8,475	)	$	3,275
Acquisition-related – amortization⁽¹⁾		461			459			919			917
Acquisition-related – other costs⁽²⁾		640			35			642			37
Restructuring		14			11			48			72
IPR&D impairment		1,335			139			1,335			139
(Gain) loss from equity securities, net		(301	)		(131	)		(377	)		275
Discrete and related tax charges⁽⁴⁾		(44	)		48			2			90
Other⁽³⁾		—			—			63			—
Non-GAAP net (loss) income	$	(8,391	)	$	2,521		$	(5,842	)	$	4,806

Diluted (loss) earnings per share reconciliation:
GAAP diluted (loss) earnings per share	$	(8.45	)	$	1.56		$	(6.82	)	$	2.61
Acquisition-related – amortization⁽¹⁾		0.37			0.37			0.74			0.73
Acquisition-related – other costs⁽²⁾		0.51			0.03			0.52			0.03
Restructuring		0.01			0.01			0.04			0.06
IPR&D impairment		1.07			0.11			1.07			0.11
(Gain) loss from equity securities, net		(0.24	)		(0.10	)		(0.30	)		0.22
Discrete and related tax charges⁽⁴⁾		(0.04	)		0.04			—			0.07
Other⁽³⁾		—			—			0.05			—
Non-GAAP diluted (loss) earnings per share	$	(6.75	)	$	2.01		$	(4.70	)	$	3.82

GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION – (Continued) (unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions, except percentages and per share amounts)		2026			2025			2026			2025
Non-GAAP adjustment summary:
Cost of goods sold adjustments	$	579		$	579		$	1,156		$	1,158
Research and development expenses adjustments		335			41			352			81
IPR&D impairment adjustments		1,750			190			1,750			190
Selling, general and administrative expenses adjustments		400			7			488			43
Total non-GAAP adjustments to costs and expenses		3,065			817			3,746			1,472
Other (income) expense, net, adjustments		(343	)		(142	)		(485	)		284
Total non-GAAP adjustments before income taxes		2,722			675			3,262			1,757
Income tax effect of non-GAAP adjustments above		(574	)		(162	)		(631	)		(316	)
Discrete and related tax charges⁽⁴⁾		(44	)		48			2			90
Total non-GAAP adjustments to net income	$	2,105		$	560		$	2,633		$	1,530

____________________
⁽¹⁾	Relates to amortization of acquired intangibles.
⁽²⁾	Adjustments include integration expenses and contingent consideration fair value adjustments associated with Gilead’s recent acquisitions.
⁽³⁾	Adjustments include donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the first quarter of 2026.
⁽⁴⁾	Represents discrete and related deferred tax charges or benefits primarily associated with acquisition-related adjustments and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.

GILEAD SCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE⁽¹⁾ (unaudited)

(in millions, except percentages and per share amounts)	Provided February 10, 2026	Updated May 7, 2026	Updated August 4, 2026
Projected product gross margin GAAP to non-GAAP reconciliation:
GAAP projected product gross margin	~ 79.0%	~ 79.0%	~ 79.0%
Acquisition-related expenses	~ 8.0%	~ 8.0%	~ 8.0%
Non-GAAP projected product gross margin	~ 87.0%	~ 87.0%	~ 87.0%

Projected operating income (loss) GAAP to non-GAAP reconciliation:
GAAP projected operating income (loss)	$11,400 – $11,900	$(1,000) – $(500)	$(2,250) – $(1,850)
Acquisition-related, IPR&D impairment, restructuring and other expenses	~ 2,400	~ 3,400	~ 5,150
Non-GAAP projected operating income	$13,800 – $14,300	$2,400 – $2,900	$2,900 – $3,300

Projected effective tax rate GAAP to non-GAAP reconciliation:⁽²⁾
GAAP projected effective tax rate	~ 21%	~ (150%) – (220%)	~ (80%) – (90%)
Income tax effect of above non-GAAP adjustments and fair value adjustments of equity securities, and discrete and related tax adjustments	(~ 1%)	NM	NM
Non-GAAP projected effective tax rate	~ 20%	~ 190% – 140%	~ 140% – 115%

Projected diluted earnings (loss) per share GAAP to non-GAAP reconciliation:
GAAP projected diluted earnings (loss) per share	$6.75 – $7.15	$(3.25) – $(2.85)	$(3.75) – $(3.40)
Acquisition-related, IPR&D impairment, restructuring and other expenses, fair value adjustments of equity securities and discrete and related tax adjustments	~ 1.70	~ 2.20	~ 3.10
Non-GAAP projected diluted earnings (loss) per share	$8.45 – $8.85	$(1.05) – $(0.65)	$(0.65) – $(0.30)

NM – Not Meaningful
⁽¹⁾	Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with transfers of intangible assets from a foreign subsidiary to Ireland and the United States.
⁽²⁾	The GAAP and non-GAAP projected effective tax rates for the August 4, 2026 update include the impact of Acquired IPR&D expenses related to the acquisitions of Arcellx, Tubulis and Ouro Medicines, which are not deductible for tax purposes. Without these Acquired IPR&D expenses, the GAAP and non-GAAP projected effective tax rate for FY26 would be ~21% and ~20%, respectively.

GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

(in millions)	June 30, 2026		December 31, 2025
Assets
Cash, cash equivalents and marketable debt securities	$	3,179	$	10,605
Accounts receivable, net		5,055		4,913
Inventories⁽¹⁾		4,298		4,368
Property, plant and equipment, net		5,833		5,606
Intangible assets, net		14,032		16,978
Goodwill		8,314		8,314
Other assets		8,652		8,239
Total assets	$	49,362	$	59,023
Liabilities and Stockholders’ Equity
Current liabilities	$	11,020	$	11,813
Long-term liabilities		26,598		24,592
Stockholders’ equity⁽²⁾		11,744		22,618
Total liabilities and stockholders’ equity	$	49,362	$	59,023


⁽¹⁾	Includes current and long-term inventories, which are disclosed separately in the notes to our financial statements in Form 10-K and Form 10-Q.
⁽²⁾	As of June 30, 2026 and December 31, 2025, there were 1,241 shares of common stock issued and outstanding.

GILEAD SCIENCES, INC. SELECTED CASH FLOW INFORMATION (unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions)		2026			2025			2026			2025
Net cash provided by operating activities	$	3,573		$	827		$	6,117		$	2,584
Net cash used in investing activities		(10,347	)		(2,116	)		(8,577	)		(2,531	)
Net cash provided by (used in) financing activities		2,344			(1,566	)		(1,895	)		(4,993	)
Effect of exchange rate changes on cash and cash equivalents		(19	)		73			(30	)		92
Net change in cash and cash equivalents		(4,450	)		(2,782	)		(4,385	)		(4,848	)
Cash and cash equivalents at beginning of period		7,628			7,926			7,564			9,991
Cash and cash equivalents at end of period	$	3,179		$	5,144		$	3,179		$	5,144

	Three Months Ended						Six Months Ended
	June 30,						June 30,
(in millions)		2026			2025			2026			2025
Net cash provided by operating activities	$	3,573		$	827		$	6,117		$	2,584
Purchases of property, plant and equipment		(140	)		(107	)		(257	)		(211	)
Free cash flow⁽¹⁾	$	3,432		$	720		$	5,859		$	2,373


⁽¹⁾	Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.

GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY (unaudited)

			Three Months Ended				Six Months Ended
			June 30,				June 30,
(in millions)			2026		2025		2026		2025
HIV
Biktarvy	U.S.	$	2,981	$	2,799	$	5,553	$	5,272
	Europe		468		429		905		804
	Rest of World		323		302		675		603
			3,772		3,530		7,133		6,679
Descovy	U.S.		921		601		1,682		1,139
	Europe		23		24		46		45
	Rest of World		23		28		46		55
			967		653		1,774		1,239
Genvoya	U.S.		236		322		451		627
	Europe		37		40		70		79
	Rest of World		16		16		32		35
			289		377		553		741
Odefsey	U.S.		171		221		324		436
	Europe		58		66		117		123
	Rest of World		10		11		19		20
			239		298		461		579
Symtuza – Revenue share⁽¹⁾	U.S.		105		88		211		170
	Europe		30		33		59		62
	Rest of World		3		3		5		6
			138		124		275		238
Yeztugo	U.S.		223		15		382		15
	Europe		—		—		—		—
	Rest of World		9		—		16		—
			232		15		397		15
Other HIV⁽²⁾	U.S.		23		50		59		101
	Europe		24		33		51		63
	Rest of World		10		9		19		19
			56		92		129		183
Total HIV	U.S.		4,659		4,096		8,663		7,760
	Europe		640		624		1,248		1,177
	Rest of World		393		368		812		738
			5,693		5,088		10,723		9,675

GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY – (Continued) (unaudited)

		Three Months Ended		Six Months Ended
		June 30,		June 30,
(in millions)		2026	2025	2026	2025
Liver Disease
Livdelzi	U.S.	147	74	261	114
	Europe	20	4	39	4
	Rest of World	—	—	—	—
		167	78	300	118
Sofosbuvir / Velpatasvir⁽³⁾	U.S.	142	184	283	351
	Europe	81	81	141	161
	Rest of World	80	76	162	175
		303	342	586	687
Vemlidy	U.S.	124	122	215	222
	Europe	13	13	27	24
	Rest of World	152	117	284	257
		289	252	526	504
Other Liver Disease⁽⁴⁾	U.S.	20	33	35	61
	Europe	79	72	157	148
	Rest of World	19	19	40	35
		118	123	232	244
Total Liver Disease	U.S.	433	413	795	748
	Europe	193	170	363	338
	Rest of World	251	211	486	467
		877	795	1,644	1,553
Veklury
Veklury	U.S.	14	51	126	250
	Europe	2	19	17	41
	Rest of World	7	50	25	132
		23	121	167	423
Oncology
*Cell Therapy*
Tecartus	U.S.	29	41	59	82
	Europe	34	41	71	72
	Rest of World	8	9	16	17
		70	92	146	171
Yescarta	U.S.	132	162	252	321
	Europe	139	154	285	304
	Rest of World	75	77	142	154
		346	393	679	779
Total Cell Therapy	U.S.	161	203	311	403
	Europe	173	196	356	376
	Rest of World	83	86	157	171
		417	485	824	949
*Trodelvy*
Trodelvy	U.S.	307	224	560	405
	Europe	92	96	187	171
	Rest of World	57	44	112	81
		457	364	859	657
Total Oncology	U.S.	468	427	871	808
	Europe	265	291	543	547
	Rest of World	140	131	269	252
		873	849	1,683	1,606

GILEAD SCIENCES, INC. PRODUCT SALES SUMMARY – (Continued) (unaudited)

			Three Months Ended				Six Months Ended
			June 30,				June 30,
(in millions)			2026		2025		2026		2025
Other
AmBisome	U.S.		4		7		11		13
	Europe		47		65		106		132
	Rest of World		59		56		131		123
			110		129		248		268
Other⁽⁵⁾	U.S.		22		44		61		91
	Europe		8		8		16		16
	Rest of World		21		21		32		35
			51		73		109		143
Total Other	U.S.		26		52		72		104
	Europe		55		73		122		149
	Rest of World		80		77		163		158
			161		202		357		410
Total product sales	U.S.		5,601		5,038		10,527		9,669
	Europe		1,155		1,178		2,292		2,251
	Rest of World		872		838		1,755		1,747
		$	7,627	$	7,054	$	14,574	$	13,668


⁽¹⁾	Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.
⁽²⁾	Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.
⁽³⁾	Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
⁽⁴⁾	Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Sovaldi, Viread and Vosevi.
⁽⁵⁾	Includes Cayston, Jyseleca, Letairis and Zydelig.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804436824/en/

Investors:

Jacquie Ross, CFA

[email protected]

Media:

Ashleigh Koss

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: COVID-19 FDA Hospitals Clinical Trials Biotechnology AIDS Health Pharmaceutical Oncology

MEDIA:

Logo

August 4, 2026 9:39 pm

AIxCrypto Announces Second Quarter 2026 Earnings Conference Call Details

PR Newswire

LOS ANGELES, Aug. 4, 2026 /PRNewswire/ — AIxCrypto Holdings, Inc. (NASDAQ: AIXC) (“AIxC” or the “Company”), a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers, today announced that the Company will hold a conference call to discuss its financial results for the second quarter ended June 30, 2026 at 4:30 PM Pacific Time (7:30 PM Eastern Time) on Friday, Aug 7, 2026.

AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: [email protected]. We welcome your participation and appreciate your continued support.

A live webcast of the conference call will be available in the Events section of the Company’s IR website at https://investors.aixcrypto.ai/news-events/events. A replay of the webcast, along with the earnings presentation, will be available on the website shortly after the conclusion of the call.

About AIxCrypto Holdings, Inc.

AIxCrypto Holdings, Inc. (Nasdaq: AIXC) is a Nasdaq-listed technology company building a three-layer architecture spanning the infrastructure, protocol, and application layers. Through the convergence of AI Agents and Embodied AI (EAI) devices, AIXC is developing technology intended to enable heterogeneous intelligent entities—robots, smart vehicles, and other edge devices—to autonomously discover, collaborate, and execute tasks with one another without centralized intermediaries, driving the advancement of the Silicon Economy.

FORWARD LOOKING STATEMENTS:

This communication — including any presentation, press release, investor materials or other document of which it forms a part (this “Communication”) — contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws, regarding AIxCrypto Holdings, Inc. (“AIxCrypto,” the “Company,” “us,” “our,” or “we”) and our industry. All statements, whether written or oral, other than statements of historical fact — including any financial projections and any statements regarding future events, our strategy, plans, objectives, expectations, or anticipated actions or results — are forward-looking statements. You can often identify forward-looking statements by words such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely,” or “continue,” or the negative of these terms or other similar expressions; the absence of these words does not mean a statement is not forward-looking. These statements reflect our current expectations and projections about future events as of the date of this Communication and are necessarily based on estimates and assumptions that, while considered reasonable by management, are inherently uncertain. AIxCrypto can give no assurance that such forward-looking statements or financial projections will prove to be correct.

Actual results may differ materially from those expressed or implied by these forward-looking statements as a result of numerous risks and uncertainties, both general and specific, including, but not limited to: business, economic, market and capital-market conditions; the heavily regulated industry in which we operate; current or future laws or regulations and new interpretations of existing laws or regulations; the inherent volatility and regulatory uncertainty associated with digital assets and cryptocurrencies; evolving money-transmission, payments and digital-asset regulatory requirements applicable to our payment and settlement arrangements; risks associated with the early-stage and beta nature of our operations, including our dependence on third-party merchants and service providers and our ability to scale our platform; risks related to our expansion into new markets, jurisdictions, services and operating modalities, including aerial and unmanned aircraft operations, and the regulatory approvals and clearances required for such operations; changes in market demand for, and the pricing of, our products and services; our relationships with our customers and business partners; our ability to successfully define, design and release new products in a timely manner that meet our customers’ needs; competition in our industry; the failure of counterparties to perform their contractual obligations; systems, network, telecommunications or service disruptions, failures or cyber-attacks; our ability to obtain additional financing on reasonable terms or at all; litigation costs and outcomes; our ability to maintain and enforce our intellectual property rights and to defend against third-party claims of infringement; our ability to attract, retain and motivate qualified personnel; and our ability to manage our growth. This list of factors is not exhaustive. Additional risks and uncertainties are described more fully in our filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025 and our subsequent filings, which are available on the SEC’s website at www.sec.gov.

The forward-looking statements in this Communication speak only as of the date hereof. Except as required by law, neither AIxCrypto nor any other person undertakes any obligation to update or revise any forward-looking statement or financial projection set out herein, whether as a result of new information, future events or otherwise. This Communication is provided for informational purposes only, does not constitute investment, tax or legal advice or any investment recommendation, and does not take into account the investment objectives or financial situation of any person. AIxCrypto reserves the right to amend or replace the information contained herein, in whole or in part, at any time, and undertakes no obligation to notify any recipient thereof. Readers are cautioned not to place undue reliance on these forward-looking statements. This caution is made under, and these forward-looking statements are intended to be covered by, the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.

View original content:https://www.prnewswire.com/news-releases/aixcrypto-announces-second-quarter-2026-earnings-conference-call-details-302843169.html

SOURCE AIxCrypto Holdings, Inc.

August 4, 2026 9:33 pm

Grace Therapeutics Announces $10 Million Private Placement

Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028

PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it has entered into a securities purchase agreement for a private placement financing with new and existing fundamental investors. The financing is expected to result in aggregate gross proceeds to the Company of approximately $10 million, before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the financing to support the manufacturing and regulatory work needed to advance GTx-104.

Pursuant to the terms of the securities purchase agreement, Grace Therapeutics will issue an aggregate of 4,761,904 shares of common stock at a price of at $2.10 per share. The private placement is being priced at-the-market under the rules of the Nasdaq Stock Market. The financing is expected to close on August 6, 2026, subject to the satisfaction of customary closing conditions.

The Company expects the net proceeds from the private placement, together with existing cash and cash equivalents, to extend the Company’s cash runway to the end of calendar 2028.

In parallel, the Company has initiated a dual-source manufacturing strategy for GTx-104 to mitigate potential remediation issues from the Company’s current contract manufacturer and provide flexibility. As such, a technology transfer to a second, U.S.-based contract manufacturer is already underway. The timing of New Drug Application (“NDA”) resubmission will reflect the manufacturing pathway that reaches readiness first: either (i) the U.S.-based facility, which would require completion of a full chemistry, manufacturing, and controls (“CMC”) package supported by 12 months of stability data following the technology transfer; or (ii) the Company’s current contract manufacturer, if it successfully remediates its FDA compliance issues and is able to support the NDA sooner. The Company is also advancing efforts to address the remaining CMC and non-clinical items identified in FDA’s Complete Response Letter (“CRL”) to the NDA, though the Company expects that manufacturing readiness, rather than these items, will be the key driver of NDA resubmission timing.

Craig-Hallum is acting as the sole placement agent for the private placement.

The offer and sale of the foregoing securities are being made in a transaction not involving a public offering, and the securities have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock purchased in the private placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state.

About aneurysmal Subarachnoid Hemorrhage (aSAH)

aSAH is bleeding over the surface of the brain in the subarachnoid space between the brain and the skull, which contains blood vessels that supply the brain. A primary cause of such bleeding is the rupture of an aneurysm in the brain. The result is aSAH, a relatively uncommon type of stroke that accounts for about 5% of all strokes and an estimated 42,500 U.S. hospital treated patients.

About GTx-104

GTx-104 is a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs. The unique nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. GTx-104 provides a convenient IV delivery of nimodipine in the Intensive Care Unit potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Intravenous delivery of GTx-104 also has the potential to lower food effects, drug-to-drug interactions, and eliminate potential dosing errors. Further, GTx-104 has the potential to better manage hypotension in aSAH patients. GTx-104 has been administered in over 200 patients and healthy volunteers and was well tolerated with significantly lower inter- and intra-subject pharmacokinetic variability compared to nimodipine oral capsules.

About Grace Therapeutics

Grace Therapeutics, Inc. (Grace Therapeutics or the Company) is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery. Grace Therapeutics’ lead clinical asset, GTx-104, is an IV infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. GTx-104 has been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States if certain conditions are met at NDA approval, and additional intellectual property protection with 52 granted and pending patents.

For more information, please visit:
www.gracetx.com
.

Forward-Looking Statements

Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Grace Therapeutics to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements containing the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “estimates,” “potential,” “should,” “may,” “will,” “plans,” “continue,” “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The forward-looking statements in this press release, including statements regarding the financing, the intended use of proceeds from the financing, the total investment amount to be raised in connection with the financing, the timing of the closing of the financing, the future prospects of the Company’s GTx-104 drug candidate; the Company’s belief that the issues identified by the FDA in the CRL can be successfully addressed in the Company’s resubmission of the NDA for GTx-104; the Company’s planned approach to addressing the items cited in the CRL following its Type A meeting with the FDA and receipt of the official meeting minutes; the Company’s dual source manufacturing strategy, including remediation at its current contract manufacturer and technology transfer to a second, U.S.-based contract manufacturer; the timing and outcome of any FDA reinspection of the current contract manufacturer; the Company’s plans to complete the required non-clinical studies; and the Company’s plans to report progress against key milestones; GTx-104’s potential to bring enhanced treatment options to patients suffering from aSAH; the ability of GTx-104 to potentially eliminate the need for nasogastric tube administration in unconscious or dysphagic patients; the potential of GTx-104 to lower food effects, drug-to-drug interactions, and to eliminate potential dosing errors; the potential of GTx-104 to better manage hypotension in aSAH patients; and the Company’s intellectual property estate for GTx-104, are based upon Grace Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the financing may not close due to counterparty risk or otherwise, (ii) the timing and success of any regulatory resubmission of the NDA for GTx-104; (iii) the timing of any FDA reinspection of the Company’s current contract manufacturer, and that facility’s compliance status, which are determined by the FDA and outside the Company’s control, and the FDA’s position that it will not approve the NDA while the facility remains in an unacceptable compliance status; (iv) the ability of a second, U.S.-based contract manufacturer to generate the required stability and analytical data and to complete a product-specific pre-approval inspection; (v) the need to complete additional non-clinical studies; (vi) the requirement that any resubmission comprehensively address all items cited in the CRL and the risk of review delay; (vii) the Company’s potential need for additional capital, which may not be available on acceptable terms; (viii) changes to regulatory pathways; (ix) the Company’s ability to protect its intellectual property for GTx-104; and (x) legislative, regulatory, political and economic developments. The foregoing list of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in the “Special Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2026 filed with the Securities and Exchange Commission (SEC) and other documents that have been and will be filed by Grace Therapeutics from time to time with the SEC and Canadian securities regulators. All forward-looking statements contained in this press release speak only as of the date on which they were made. Grace Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws.

For more information, please contact:

Grace Therapeutics Contact:

Prashant Kohli
Chief Executive Officer
Tel: 609-322-1602
Email: [email protected]
www.gracetx.com

Investor Relations:

LifeSci Advisors
Mike Moyer
Managing Director
Phone: 617-308-4306
Email: [email protected]

August 4, 2026 9:32 pm

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

SAN CARLOS, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) — Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced the pricing of its upsized initial public offering of 17,000,000 shares of its common stock at an initial public offering price of $17.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $289.0 million. All shares of common stock to be sold in the offering will be sold by Attovia. In addition, Attovia has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Attovia’s common stock is expected to begin trading on the Nasdaq Global Market on August 5, 2026, under the symbol “ATTO.” The offering is expected to close on August 6, 2026, subject to the satisfaction of customary closing conditions.

Morgan Stanley, Leerink Partners, Citigroup and RBC Capital Markets are acting as joint book-running managers for the offering. LifeSci Capital is acting as a passive book-running manager for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and was declared effective on August 4, 2026. The offering is being made only by means of a prospectus. A copy of the final prospectus may be obtained, when available, from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, NY 10014 or by email at [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105 or by email at [email protected]; Citigroup Global Markets, Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-800-831-9146; and RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York, NY 10281, by telephone at 1-877-822-4089 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Attovia, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Attovia Therapeutics, Inc.

Attovia is a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need. All of its product candidates have been internally discovered using our ATTOBODY biparatopic biologics platform. Attovia’s ATTOBODY platform uses an evolution-driven, high-throughput process which allows for rapid discovery and creation of a high diversity of potential product candidates.

Attovia’s lead programs include ATTO-1310, an anti-IL-31 therapeutic in clinical development for chronic pruritic diseases, ATTO-2306, a bispecific antibody targeting IL-31 and IL-13 in IND-enabling studies for atopic dermatitis and other immune-mediated skin diseases, and ATTO-1091, a trispecific antibody targeting TL1A, IL-23p19, and integrin α4β7 in IND-enabling studies for inflammatory bowel disease. Attovia’s other programs include highly innovative conditional ‘AND’ gated bispecific immune cell survival blockers and multispecifics.

Investor and Media Contact

PJ Kelleher
LifeSci Advisors
617-430-7579
[email protected]

August 4, 2026 9:32 pm

BZAI INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Blaize Holdings, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

ATLANTA, Aug. 04, 2026 (GLOBE NEWSWIRE) — A shareholder class action lawsuit has been filed against Blaize Holdings, Inc. (“Blaize”) (NASDAQ: BZAI). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Blaize announced transactions with entities wholly unequipped to conduct meaningful business in order to create an appearance of growth; and (2) Blaize improperly recognized revenue.

If you purchased Blaize shares between July 18, 2025 and April 28, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at [email protected], by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/blaize-holdings/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is October 5, 2026.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. 

CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]

August 4, 2026 9:32 pm

Gap Inc. to Report Second Quarter Fiscal 2026 Results on August 27

PR Newswire

SAN FRANCISCO, Aug. 4, 2026 /PRNewswire/ — Gap Inc. (NYSE: GAP) will report its second quarter fiscal 2026 financial results by press release on Thursday, August 27, 2026, at approximately 1:15 p.m. Pacific Time.

In addition, the company will host a conference call to review its second quarter fiscal 2026 results on Thursday, August 27, 2026, beginning at approximately 2:00 p.m. Pacific Time.

A live webcast of the conference call will be available online at investors.gapinc.com. A replay of the webcast will be available at the same location.

About Gap Inc.
Gap Inc., a purpose-driven house of iconic brands, is the largest specialty apparel company in America. Its Old Navy, Gap, Banana Republic, and Athleta brands offer clothing, accessories, and lifestyle products for men, women and children available worldwide through company-operated and franchise stores, and e-commerce sites. Since 1969, Gap Inc. has created products and experiences that shape culture, while doing right by employees, communities and the planet through its commitment to bridge gaps to create a better world. For more information, please visit www.gapinc.com.

Investor Relations Contact:

Shirley Martin

[email protected]

Media Relations Contact:

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/gap-inc-to-report-second-quarter-fiscal-2026-results-on-august-27-302843107.html

SOURCE Gap Inc.

August 4, 2026 9:32 pm

BABA INVESTOR ALERT: Alibaba Group Holding Limited Investors with Substantial Losses Have Opportunity to Lead the Alibaba Class Action Lawsuit

PR Newswire

SAN DIEGO, Aug. 4, 2026 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Alibaba Group Holding Limited (NYSE: BABA) publicly traded securities between June 26, 2025 and June 24, 2026, inclusive (the “Class Period”), have until October 5, 2026 to seek appointment as lead plaintiff of the Alibaba class action lawsuit. Captioned Wistisen v. Alibaba Group Holding Limited, No. 26-cv-06654 (S.D.N.Y.), the Alibaba class action lawsuit charges Alibaba and Alibaba’s Chief Executive Officer with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the

Alibaba

class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-alibaba-group-holding-limited-class-action-lawsuit-baba.html

You can also contact attorneys

Ken Dolitsky

or

Michael Albert
of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].

CASE ALLEGATIONS: Alibaba, through its subsidiaries, provides technology infrastructure and marketing reach to help merchants, brands, retailers, and other businesses.

The Alibaba class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) under the National Defense Authorization Act, any entities directly or indirectly controlled by or affiliated with the Chinese Ministry of Industry and Information Technology were considered a Chinese military company; (ii) Alibaba was directly or indirectly controlled by or affiliated with the Chinese Ministry of Industry and Information Technology; (iii) the risk of Alibaba carrying out distillation attacks against third-party AI models was not a mere hypothetical or inadvertent, but ongoing; and (iv) as a result, defendants’ public statements about Alibaba’s business, operations, and prospects were materially false and/or misleading at all relevant times.

On June 8, 2026, after market hours, the U.S. Department of Defense allegedly released an updated list identifying Chinese military companies that included Alibaba due to its direct or indirect control by or affiliation with the Chinese Ministry of Industry and Information Technology. On this news, the price of Alibaba’s American Depositary Shares (“ADSs”) declined nearly 4%, according to the complaint.

On June 24, 2026, shortly before the markets closed, Bloomberg published an article titled “Anthropic Accuses Alibaba of ‘Illicitly’ Accessing AI Models.” According to the complaint, the article stated in part that “Anthropic said that a campaign by operators linked to Alibaba’s Qwen AI lab targeted Claude’s most prized capabilities, including software engineering and agentic reasoning, according to a letter that the AI startup sent to several US senators and White House officials.” The article allegedly also added that “Anthropic warned that Alibaba and other Chinese labs are making systematic and unauthorized use of results from leading US models to develop a rival generation of chatbots at a fraction of the cost via a practice known as adversarial distillation.” On this news, the price of Alibaba’s ADSs fell 2.7% on June 24, 2026, and 4.7% further on June 25, 2026, according to the complaint.

THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Alibaba publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Alibaba class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Alibaba class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Alibaba class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Alibaba class action lawsuit.

ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:

Robbins Geller Rudman & Dowd LLP
Ken Dolitsky
Michael Albert
655 W. Broadway, Suite 1900, San Diego, CA 92101
800/851-7783
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/baba-investor-alert-alibaba-group-holding-limited-investors-with-substantial-losses-have-opportunity-to-lead-the-alibaba-class-action-lawsuit-302843053.html

SOURCE Robbins Geller Rudman & Dowd LLP

August 4, 2026 9:32 pm

Santander Receives Federal Reserve Approval for the Acquisition of Webster Financial Corporation

MADRID & STAMFORD, Conn.–(BUSINESS WIRE)–
Banco Santander, S.A. (“Santander”) and Webster Financial Corporation (“Webster”) today announced that they have received the required approval from the Board of Governors of the Federal Reserve System for Santander’s previously announced acquisition of Webster, the holding company for Webster Bank, N.A., a diversified U.S. retail and commercial bank. This follows the approval by the Office of the Comptroller of the Currency on June 12, 2026, and the authorization granted by the European Central Bank on July 21, 2026. The transaction is now expected to close on August 20, 2026.

Ana Botín, Executive Chair of Santander, said: “Santander US and Webster are a perfect match. Together, supported by Santander’s global platforms, technology and expertise, we will create a stronger bank with the scale to better serve our customers and communities. This combination will strengthen our position in one of the world’s most attractive banking markets and put us firmly on track to build one of the highest-performing banks among our U.S. peers.”

Christiana Riley, CEO and President of Santander Holdings USA, Inc. (“Santander US”), said: “We are pleased to be one step closer to this important, strategic acquisition that will expand our scale and round out our U.S. business model. Bringing together these two highly complementary businesses, Santander will be well positioned to better serve our customers and clients, while helping local communities prosper. We are excited for this next chapter for Santander.”

John Ciulla, Chairman and CEO of Webster, said: “This is an exciting moment that will allow us to soon bring together our two great organizations to benefit our customers and communities. Santander’s expanded scale, enhanced capabilities and financial strength will help us to deepen local relationships and build upon the trusted partnership that Webster customers have come to expect from us.”

The transaction is expected to strengthen Santander’s U.S. franchise and accelerate the delivery of its financial objectives. Once integrated, Santander expects its U.S. business to achieve a return on tangible equity (RoTE) of around 18% by 2028, while the transaction is expected to generate approximately 7–8% earnings per share accretion and an estimated 15% return on invested capital, all by 2028.

Upon closing, most of Webster’s businesses will become part of Santander Bank, N.A., Santander’s banking franchise in the United States. Until the transaction closes, Santander and Webster will continue to operate independently. Customers do not need to take any action at this time, and accounts, products, and services will continue to operate as they do today. Any future changes will be communicated in advance of implementation.

Banco Santander (SAN SM) is a leading commercial bank, founded in 1857 and headquartered in Spain and one of the largest banks in the world by market capitalization. The group’s activities are consolidated into five global businesses: Retail & Commercial Banking, Openbank, Corporate & Investment Banking (CIB), Wealth Management & Insurance and Payments. This operating model allows the bank to better leverage its unique combination of global scale and local leadership. Santander aims to be the best open financial services platform providing services to individuals, SMEs, corporates, financial institutions and governments. The bank’s purpose is to help people and businesses prosper in a simple, personal and fair way. As of June 30, 2026, Banco Santander had €1.5 trillion in total funds, more than 182 million customers, 6,500 branches and 185,000 employees.

Webster Financial Corporation (“Webster”) (NYSE:WBS) is the holding company for Webster Bank, N.A. (“Webster Bank”). Founded in 1935 and headquartered in Stamford, CT, Webster is a values-driven organization with more than $80 billion in total assets. Webster Bank is a commercial bank that provides a wide range of financial products and services to businesses, individuals, and families across three differentiated lines of business: Commercial Banking, Healthcare Financial Services, and Consumer Banking. While its core footprint spans the Northeast from the New York metropolitan area to Rhode Island and Massachusetts, certain businesses operate in extended geographies. Webster Bank is a member of the FDIC and an equal housing lender. For more information about Webster, including past press releases and the latest annual report, visit the Webster website at www.websterbank.com

Important information

Non-IFRS and alternative performance measures

Banco Santander, S.A. (“Santander”) cautions that this report may contain financial information prepared according to International Financial Reporting Standards (IFRS) and taken from our consolidated financial statements, as well as alternative performance measures (APMs) as defined in the Guidelines on Alternative Performance Measures issued by the European Securities and Markets Authority (ESMA) on 5 October 2015, and other non-IFRS measures. The financial measures referred to in this report that are considered APMs or non-IFRS measures were calculated with information from Grupo Santander; however, they are neither defined or detailed in the applicable financial reporting framework nor audited or reviewed by our auditors. We use the APMs and non-IFRS measures when planning, monitoring and evaluating our performance. We consider them to be useful metrics for our management and investors to compare operating performance between accounting periods.

Nonetheless, the APMs and non-IFRS measures are supplemental information; their purpose is not to substitute the IFRS measures. Furthermore, other companies, including some in our industry, may calculate or use APMs and non-IFRS measures differently, thus making them less useful for comparison purposes. APMs using environmental, social and governance labels have not been calculated in accordance with the Taxonomy Regulation or with the indicators for principal adverse impact in the Sustainable Finance Disclosure Regulation (SFDR; EU Reg. 2019/2088).

[For more details on APMs and non-IFRS measures, please see the 2025 Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the SEC) on 27 February 2026 (https://www.santander.com/content/dam/santander-com/es/documentos/informacion-sobre-resultados-semestrales-y-anuales-suministrada-a-la-sec/2026/sec-2025-annual-20-f-2025-disponible-solo-en-ingles-es.pdf) as well as the section “Alternative performance measures” of Santander’s 2025 Annual Report, which was published on 25 February 2026 (https://www.santander.com/content/dam/santander-com/en/documentos/informe-financiero-anual/2025/ifa-2025-consolidated-annual-financial-report-en.pdf), except with respect to the information and the audited financial statements included therein and superseded by the information and the audited financial statements included in our Report on Form 6-K furnished to the SEC on April 1, 2026 relating to certain recast financial information as a result of certain changes to the presentation of the Group’s financial information (https://www.santander.com/content/dam/santander-com/en/documentos/informacion-sobre-resultados-semestrales-y-anuales-suministrada-a-la-sec/2026/sec-recast-of-certain-financial-information-and-related-disclosure-for-the-three-years-ended-31-december-2025-en.pdf) as well as the section “Alternative performance measures” of our second quarter financial report, which was published on 22 July 2026 (https://www.santander.com/en/shareholders-and-investors/financial-and-economic-information/quarterly-results).

Forward-looking statements

Santander hereby warns that this report may contain ‘forward-looking statements’, as defined by the US Private Securities Litigation Reform Act of 1995. Such statements can be understood through words and expressions like ‘expect’, ‘project’, ‘anticipate’, ‘should’, ‘intend’, ‘probability’, ‘risk’, ‘VaR’, ‘RoRAC’, ‘RoRWA’, ‘TNAV’, ‘target’, ‘goal’, ‘objective’, ‘estimate’, ‘future’, ‘ambition’, ‘aspiration’, ‘commitment’, ‘commit’, ‘focus’, ‘pledge’ and similar expressions. They include (but are not limited to) statements on future business development, shareholder remuneration policy and non-financial information. However, various risks, uncertainties and other important factors may lead to developments and results that differ materially from those anticipated, expected, projected or assumed in forward-looking statements. The important factors below (and others mentioned in this report), as well as other unknown or unpredictable factors, could affect our future development and results and could lead to outcomes materially different from what our forward-looking statements anticipate, expect, project or assume:

general economic or industry conditions (e.g., an economic downturn; higher volatility in the capital markets; inflation; deflation; changes in demographics, consumer spending, investment or saving habits; and the effects of the armed conflicts in Ukraine, or the outbreak of public health emergencies in the global economy) in areas where we have significant operations or investments;
exposure to operational risks, including cyberattacks, data breaches, data losses and other security incidents;
exposure to market risks (e.g., risks from interest rates, foreign exchange rates, equity prices and new benchmark indices);
potential losses from early loan repayment, collateral depreciation or counterparty risk;
political instability in Spain, the UK, other European countries, Latin America and the US;
changes in monetary, fiscal and immigration policies and trade tensions, including the imposition of tariffs and retaliatory responses;
legislative, regulatory or tax changes (including regulatory capital and liquidity requirements) and greater regulation prompted by financial crises;
acquisitions, integrations, divestitures and challenges arising from deviating management’s resources and attention from other strategic opportunities and operational matters;
reputational risk and potential adverse reactions of stakeholders, including adverse effects on the market price of our securities
climate-related conditions, regulations, targets and weather events;
uncertainty over the scope of actions that may be required by us, governments and other to achieve goals relating to climate, environmental and social matters, as well as the evolving nature of underlying science and potential conflicts and inconsistencies among governmental standards and regulations;
our own decisions and actions, including those affecting or changing our practices, operations, priorities, strategies, policies or procedures; and
changes affecting our access to liquidity and funding on acceptable terms, especially due to credit spread shifts or credit rating downgrade for the entire group or core subsidiaries.

Additionally, Webster Financial Corporation’s (“Webster”) and Santander’s actual results, financial condition and achievements may differ materially from those indicated in these forward-looking statements. Important factors that could cause Webster’s and Santander’s actual results, financial condition and achievements to differ materially from those indicated in such forward-looking statements include, in addition to those set forth in Webster’s and Santander’s filings with the SEC: (1) the risk that the cost savings, synergies and other benefits from the acquisition of Webster by Santander (the “Transaction”) may not be fully realized or may take longer than anticipated to be realized, including as a result of changes in, or problems arising from, general economic and market conditions, interest and exchange rates, monetary policy, laws and regulations and their enforcement, and the degree of competition in the geographic and business areas in which Webster and Santander operate; (2) the failure of the closing conditions in the Transaction agreement by and among Webster, Santander and a wholly owned subsidiary of Webster providing for the Transaction to be satisfied, or any unexpected delay in closing the Transaction or the occurrence of any event, change or other circumstances that could delay the Transaction or could give rise to the termination of the Transaction agreement; (3) the outcome of any legal or regulatory proceedings or governmental inquiries or investigations that may be currently pending or later instituted against Webster, Santander or the combined company; (4) the possibility that the Transaction does not close when expected or at all because the remaining conditions to closing are not received or satisfied on a timely basis or at all; (5) disruption to the parties’ businesses as a result of the announcement and pendency of the Transaction; (6) the costs associated with the anticipated length of time of the pendency of the Transaction, including the restrictions contained in the definitive Transaction agreement on the ability of Webster to operate its business outside the ordinary course during the pendency of the Transaction; (7) risks related to management and oversight of the expanded business and operations of the combined company following the closing of the proposed Transaction; (8) the risk that the integration of Webster’s operations with Santander’s will be materially delayed or will be more costly or difficult than expected or that the parties are otherwise unable to successfully integrate each party’s businesses into the other’s businesses; (9) the possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (10) reputational risk and potential adverse reactions of Webster’s or Santander’s customers, employees, vendors, contractors or other business partners, including those resulting from the announcement or completion of the Transaction; (11) the dilution caused by Santander’s issuance of additional ordinary shares and corresponding American depositary shares, each representing the right to receive one of its ordinary shares (“ADSs”), in connection with the Transaction; (12) the possibility that any announcements relating to the Transaction could have adverse effects on the market price of Webster’s common stock and Santander’s ordinary shares and ADSs; (13) a material adverse change in the condition of Webster or Santander; (14) the extent to which Webster’s or Santander’s businesses perform consistent with management’s expectations; (15) Webster’s and Santander’s ability to take advantage of growth opportunities and implement targeted initiatives in the timeframe and on the terms currently expected; (16) the inability to sustain revenue and earnings growth; (17) the execution and efficacy of recent strategic investments; (18) the impact of macroeconomic factors, such as changes in general economic conditions and monetary and fiscal policy, particularly on interest rates; (19) changes in customer behavior; (20) unfavorable developments concerning credit quality; (21) declines in the businesses or industries of Webster’s or Santander’s customers; (22) the possibility that the combined company is subject to additional regulatory requirements as a result of the proposed Transaction or expansion of the combined company’s business operations following the proposed Transaction; (23) general competitive, political and market conditions and other factors that may affect future returns of Webster and Santander, including changes in asset quality and credit risk; (24) security risks, including cybersecurity and data privacy risks, and capital markets; (25) inflation; (26) the impact, extent and timing of technological changes; (27) capital management activities; (28) competitive product and pricing pressures; (29) the outcomes of legal and regulatory proceedings and related financial services industry matters; and (30) compliance with regulatory requirements. Any forward-looking statement made in this communication is based solely on information currently available to us and speaks only as of the date on which it is made.

Forward looking statements are based on current expectations and future estimates about Santander’s and third-parties’ operations and businesses and address matters that are uncertain to varying degrees, including, but not limited to, developing standards that may change in the future; plans, projections, expectations, targets, objectives, strategies and goals relating to environmental, social, safety and governance performance, including expectations regarding future execution of Santander’s and third parties’ energy and climate strategies, and the underlying assumptions and estimated impacts on Santander’s and third-parties’ businesses related thereto; Santander’s and third-parties’ approach, plans and expectations in relation to carbon use and targeted reductions of emissions; changes in operations or investments under existing or future environmental laws and regulations; and changes in government regulations and regulatory requirements, including those related to climate-related initiatives.

Forward-looking statements are aspirational, should be regarded as indicative, preliminary and for illustrative purposes only, speak only as of the date of this report and are informed by the knowledge, information and views available on such date and are subject to change without notice. Santander is not required to update or revise any forward-looking statements, regardless of new information, future events or otherwise, except as required by applicable law.

No offer or solicitation

This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”). No investment activity should be undertaken on the basis of the information contained in this communication. By making this communication available, no advice or recommendation is being given to buy, sell or otherwise deal in any securities or investments whatsoever.

Past performance does not indicate future outcomes

Statements about historical performance or growth rates must not be construed as suggesting that future performance, share price or earnings (including earnings per share) will necessarily be the same or higher than in previous periods. Nothing mentioned in this report should be taken as a profit and loss forecast.

Third Party Information

Regarding the data provided by third parties, neither Santander, nor any of its directors, managers or employees, either explicitly or implicitly, guarantees that these contents are exact, accurate, comprehensive or complete, nor are they obliged to keep them updated, nor to correct them in the case that any deficiency, error or omission were to be detected. Moreover, in reproducing these contents in by any means, Santander may introduce any changes it deems suitable, and may omit, partially or completely, any of the elements of this report, and in case of any deviation, Santander assumes no liability for any discrepancy.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804258528/en/

Media contacts

Banco Santander: [email protected]

Santander US: [email protected]

Webster: [email protected]

KEYWORDS: Connecticut Europe Spain United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

August 4, 2026 9:32 pm

C3 AI Announces New Employee Inducement Grant

C3 AI Announces New Employee Inducement Grant

REDWOOD CITY, Calif.–(BUSINESS WIRE)–
C3 AI (“C3.ai, Inc.” or the “Company”) (NYSE: AI), the Enterprise AI application software company, today announced that it granted an equity award under its 2025 Inducement Plan (the “Inducement Plan”) to Tom MacMitchell, the Company’s Senior Vice President and General Counsel, who recently joined the Company.

Effective July 30, 2026, C3 AI’s Compensation Committee of the Board of Directors approved a restricted stock unit award covering 826,901 shares of C3 AI’s Class A common stock (the “RSU Award”). Such award was granted as a material inducement in accordance with the employment inducement award exemption under the NYSE Listed Company Manual Section 303A.08.

The RSU Award will vest over a five-year term in accordance with the following schedule: subject to continued service, 165,380 RSUs will vest on the date twelve months following the July 27, 2026, vesting commencement date, with the remaining RSUs vesting in equal quarterly installments thereafter until the award is fully vested. Further, the RSU Award is subject to double-trigger acceleration: if a corporate transaction or change in control of the Company occurs during his employment and, within 36 months thereafter, he resigns for constructive termination or is terminated other than for cause, death or disability, any unvested portion of the award will accelerate in full, subject to his satisfaction of certain severance conditions, including a release of claims.

The RSU Award is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a restricted stock unit award agreement covering the award.

About C3 AI

C3 AI is the Enterprise AI application software company. C3 AI delivers a family of fully integrated products including the C3 Agentic AI Platform, an end-to-end platform for developing, deploying, and operating enterprise AI applications, C3 AI applications, a portfolio of industry-specific SaaS enterprise AI applications that enable the digital transformation of organizations globally, and C3 Generative AI, a suite of domain-specific generative AI offerings for the enterprise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804361676/en/

C3 AI Public Relations

Axicom

Mindy Nelson

830-214-4823

[email protected]

Investor Relations

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Software Technology Artificial Intelligence Apps/Applications

MEDIA:

Logo

August 4, 2026 9:32 pm

B&G Foods Declares Regular Quarterly Dividend

B&G Foods Declares Regular Quarterly Dividend

PARSIPPANY, N.J.–(BUSINESS WIRE)–
B&G Foods, Inc. (NYSE: BGS) announced today that its Board of Directors has declared a regular quarterly cash dividend of $0.095 per share of common stock. The dividend is payable on October 30, 2026 to stockholders of record as of September 30, 2026.

At the closing market price of the common stock on August 4, 2026, the current dividend rate represents an annualized yield of 10.7%. This is the 88^th consecutive quarterly dividend declared by the Board of Directors since B&G Foods’ initial public offering in October 2004.

About B&G Foods, Inc.

Based in Parsippany, New Jersey, B&G Foods and its subsidiaries manufacture, sell and distribute high-quality, branded shelf-stable and frozen foods across the United States, Canada and Puerto Rico. With B&G Foods’ diverse portfolio of more than 50 brands you know and love, including B&G, B&M, Bear Creek, College Inn, Cream of Wheat, Crisco, Dash, Kitchen Basics, Las Palmas, Mama Mary’s, Maple Grove Farms, New York Style, Ortega, Polaner, Spice Islands and Victoria, there’s a little something for everyone. For more information about B&G Foods and its brands, please visit www.bgfoods.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260804806226/en/

Investor Relations:

ICR, Inc.

Anna Kate Heller

[email protected]

Media Relations:

ICR, Inc.

Matt Lindberg

[email protected]

KEYWORDS: New Jersey United States North America

INDUSTRY KEYWORDS: Food/Beverage Manufacturing Other Manufacturing Retail Supermarket

MEDIA: